The advent of the second-generation TKIs prompted the question of whether TFR could be attempted in patients who received these agents as first-line treatment or as second-line treatment after failure of imatinib. Table 3.2 summarises outcomes for patients in TFR following treatment with a second-generation TKI. In all trials, a second molecular response could be achieved after re-initiation of the same TKI following a first molecular relapse.
